**STRATIFIED COST-EFFECTIVENESS ANALYSIS: THE RISKS AND REWARD OF LOOKING AT SUB-GROUPS**

Moderator: Henry Glick, Ph.D.
Speakers: Joseph Heyse, Ph.D.,
Jeffrey Hoch, Ph.D.,
Andrew Willan, Ph.D.

*ISPOR 9th Annual International Meeting*

**POOLED TRIAL RESULT**

- Usual result from a patient-level economic evaluation:
  - Pooled analysis from a potentially heterogeneous population, e.g.,
    - Different levels of disease severity
    - Variety of ages, genders, and races
    - Treated in different parts of the world

**INTERPRETING POOLED RESULT**

- Usual question of interpretation:
  - Does the pooled result reflect an outcome that is common to all subgroups in the study, or is it a result that fails to reflect the outcome for any subgroup?

**SO WHAT?**

- Answers touch important policy “nerves”
  - For multinational trials: How should we tailor the pooled result from a trial to individual countries?
    - Proposed methods move away from simple multiplication of trial-wide medical service use times country-specific price weights
SO WHAT (II)

- For reimbursement decisions: Can we identify selected subgroups of patients for whom therapy:
  - Is good value, and for whom we should provide reimbursement?
  - Isn’t good value, and for whom we should not provide reimbursement?

3 SPEAKERS

- Each speaker will address a different approach to answering these questions:
  - Assessment of qualitative and quantitative interaction (Heyse)
  - Net monetary benefit regression (Hoch)
  - Empirical Bayes shrinkage estimation (Willan)

GOALS OF SESSION

- TO briefly describe the methods and identify their synergies and differences
- NOT to identify one method as the über method

(Strictly enforced 12 minutes/speaker)